인쇄하기
취소

SK Chemicals’ hemophilia treatment, AFSTYLA, approved by EMA

Published: 2017-01-12 13:55:19
Updated: 2017-01-12 13:55:19

SK Chemicals(CEO Man-Hoon Park) announced, on the 10th, the hemophilia treatment ‘AFSTYLA’ acquired the final commercialization approval from the European Medicines Agency(EMA). Thus, AFSTYLA becomes the first drug entered in the EU as a biomedicine developed by Korean technology.

CSL has carried out manufacturing, global clinical trials and approval application for AFSTYLA, developed by SK Ch...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.